If you’ve seen testosterone called the libido drug women want, here’s the straight answer. As of November 20, 2026, no testosterone product is FDA-approved for women in the United States. When US clinicians prescribe testosterone for women, that use is off-label, which means a medication is prescribed for something other than its FDA-approved purpose. A Science News report on testosterone cites a Truveta estimate that prescribing rose from 0.4 to 1.8 per 1,000 women between 2018 and 2026. The FDA held a public workshop on testosterone use in menopausal women on September 17, 2026.
Disclosure: A number of the links on this page are affiliate links. The editors may earn a commission when you buy through these links. This costs you nothing extra.

Quick facts, dated 2026-11-20
| Question | Answer as of 2026-11-20 | Source |
|---|---|---|
| Is any testosterone product FDA-approved for women in the US? | No | FDA workshop page |
| Is testosterone used for women in the US off-label? | Yes, when US clinicians prescribe it for women | FDA workshop page; Science News |
| Is testosterone a controlled substance? | Yes, Schedule III | DEA anabolic steroid fact sheet |
| Which use does the 2019 consensus support? | Hypoactive sexual desire disorder (HSDD) in postmenopausal women, after a biopsychosocial assessment | 2019 Global Consensus statement |
| Where is it approved for women? | UK and Australia (Science News); also New Zealand and South Africa (Holland & Knight analysis) | Science News; Holland & Knight analysis |
Is testosterone FDA-approved for menopause?
No. Menopause isn’t a separate approval, because no testosterone product is FDA-approved for women at all. The FDA workshop on testosterone use page refers to growing off-label use and lists no approved product.
Per Science News, a 2004 FDA advisory panel unanimously rejected a testosterone patch.
Is there a blood test that diagnoses it?
The ISSWSH 2021 clinical practice guideline, as summarized by the society, says total testosterone is used for monitoring, not diagnosis.
What was the FDA workshop, and what did it ask?
The FDA’s public workshop on testosterone use in menopausal women was held on 17 September 2026. The FDA Office of Women’s Health and CDER ran it under docket FDA-2026-N-5479. Comments were open until 19 October 2026.
The workshop page names four gaps: long-term cardiovascular risk, breast cancer risk, dosing and trial endpoints.
A Holland & Knight analysis, from a law firm, reports that the FDA called the workshop a “call to action.” The same analysis says data on long-term cardiovascular risk are inadequate, breast cancer evidence is inconclusive, and safety data beyond 24 months are limited. It also says off-label use tripled in five years and covers under 0.36% of menopausal women.
What does the 2019 consensus actually support?
The 2019 Global Consensus statement was issued by the Endocrine Society and ten other societies, with a task force convened by the International Menopause Society. Its one evidence-based use is hypoactive sexual desire disorder (HSDD) in postmenopausal women, after a biopsychosocial assessment.
It says blood levels should stay no higher than those of healthy young women, and it calls for female-specific approved products. It found no evidence for other symptoms or conditions. Per the PubMed abstract of the statement, the consensus lists possible acne and hair growth, advises caution after breast cancer, and finds no cognition, general wellbeing or disease-prevention benefit. It also finds insufficient data for premenopausal women.
The ISSWSH guideline summary adds that systemic transdermal testosterone is for HSDD not primarily due to modifiable factors, that levels should stay in the premenopausal physiologic range, that compounded products are not recommended, and that long-term safety is not established.
Is testosterone approved for women outside the US?
Science News reports that testosterone for women is approved in the UK and Australia. Holland & Knight adds New Zealand and South Africa.
In Australia, the AndroFeme 1 Australian listing covers a testosterone 1% cream. Per that listing, it was registered with the TGA for HSDD in postmenopausal women on 23 November 2020, and it is to be started only after education and biopsychosocial correction fail. A registration in another country is that country’s decision, and it doesn’t change the US status.
What’s the history behind the trial results?
Per Science News, a 2004 FDA advisory panel unanimously rejected a testosterone patch, and Phase III trials in 2011 failed to beat placebo. Tami Rowen, a UCSF ob-gyn who co-authored 2025 international recommendations, tells Science News that placebo response is the biggest problem.
Per Science News, the 2025 international group says psychological therapy and Addyi have the strongest evidence.
Key dates
| Date | What happened | Source |
|---|---|---|
| 2004 | Per Science News, FDA advisory panel unanimously rejects a testosterone patch | Science News |
| 2011 | Per Science News, Phase III trials fail to beat placebo | Science News |
| 2015 | Addyi approved | Science News |
| 2019 | Global Consensus statement published; Vyleesi approved | 2019 Global Consensus statement; Science News |
| 23 November 2020 | AndroFeme 1 registered with the TGA for HSDD in postmenopausal women | Healthdirect |
| 15 December 2025 | Addyi expanded to HSDD in postmenopausal women under 65 (one clinical source says January 2026) | Urology Times |
| 17 September 2026 | FDA public workshop on testosterone use in menopausal women, docket FDA-2026-N-5479 | FDA workshop page |
| 19 October 2026 | Comment deadline for the workshop docket | FDA workshop page |
| 20 November 2026 | No testosterone product is FDA-approved for women in the US | FDA workshop page |
Who does this affect?
The question is mostly about women after menopause. The 2019 consensus’s one evidence-based use is HSDD in postmenopausal women. The consensus abstract lists insufficient data for premenopausal women. Science News reports that prescribing rose from 0.4 to 1.8 per 1,000 women between 2018 and 2026, based on a Truveta estimate it cites.
Common mix-ups
| Common mix-up | What’s true |
|---|---|
| Men’s testosterone is approved for women. | Men’s gels and creams are used off-label in women, at lower doses, per the FDA Law Blog. |
| Approved in Australia means approved in the US. | AndroFeme 1 is registered in Australia for HSDD in postmenopausal women. US status is still no approved product. |
| Addyi is a testosterone product. | Per Urology Times, Addyi is flibanserin 100 mg. |
| The 2019 consensus backs testosterone for menopause. | It supports HSDD in postmenopausal women only, after assessment. |
Is testosterone a controlled substance?
Yes. Testosterone is a Schedule III controlled substance in the United States, under the anabolic steroid framework from a 1990 law, per the DEA anabolic steroid fact sheet. For erectile dysfunction prescriptions, which are a different category, see our keeps vs hims guide.
What are the risks, and what’s still unknown?
Heart. The FDA lists long-term cardiovascular risk as a gap. Science News says heart risk is unresolved.
Breast. The FDA lists breast cancer risk as a gap, Holland & Knight calls breast cancer evidence inconclusive, and Science News says breast cancer risk is unresolved. For more on that question, see our testosterone and breast tissue research (our research library) explainer.
Skin and hair. The 2019 consensus lists possible acne and hair growth.
Formulation. Off-label practice uses men’s gels and creams at lower doses and compounded formulations, per the FDA Law Blog. ISSWSH says compounded products are not recommended.
Other FDA-approved options for low desire
Science News says Addyi was approved in 2015 and Vyleesi in 2019, and that Addyi was expanded to postmenopausal women under 65 last year. Per Urology Times, Addyi (flibanserin 100 mg) was expanded to HSDD in postmenopausal women under 65, announced 15 December 2025, with its boxed warning on alcohol and hypotension kept. Science News also reports that Lybrido is set to enter Phase III in Europe.
For a separate guide to PT-141 (bremelanotide), see our PT-141 side effects guide.
Questions you might have about weight, dose and estrogen
Will testosterone make a woman lose weight? The 2019 consensus names one evidence-based use, HSDD in postmenopausal women, so weight loss isn’t among the uses it supports.
Is 5 mg a lot for a woman? Dose questions belong with a clinician. The consensus measures doses by blood levels no higher than those of healthy young women.
What happens without estrogen? Science News cites a 2008 New England Journal of Medicine study of a testosterone patch in postmenopausal women without estrogen. Ask a clinician to walk you through what that study found and how it applies to you.
Questions to bring to a clinician
- Does my concern fit the HSDD described in the 2019 consensus, and has a biopsychosocial assessment been done?
- Which other causes, such as thyroid problems or depression, have you ruled out?
- Which FDA-approved options for low desire should we compare, such as Addyi?
- If testosterone is considered off-label, what product and formulation would be used, and is it compounded?
- What heart, breast, skin and hair-growth risks apply to my history?
- How would my levels be monitored, and what would you do with the results?
- How do Schedule III rules shape how you prescribe?
By the Integrative Health Evidence Guide Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.